Jan 16, 2019 (WiredRelease via COMTEX) — Kidney fibrosis or renal fibrosis is an unavoidable consequence of excessive growth of extracellular matrix that occurs virtually in all types of chronic kidney diseases. Renal scarring results in the progression of loss of renal function, which leads to end-stage renal failure or need for kidney dialysis treatment or transplant. Obesity and smoking are the main causes for increasing incidence of kidney fibrosis globally.
Among the various therapeutic treatments in the market, angiotensin converting enzyme inhibitor is more widely used and revenue from sales of these types of drugs is expected to contribute significantly to growth of the global kidney fibrosis treatment market over the forecast period. Owing to rising disposable income among consumers globally, and rising awareness about accessibility to treatments in hospitals etc., revenue from angiotensin converting enzyme inhibitor is expected to continue its dominance over the forecast period.
Other factors fueling growth of this market include increasing aging population, income saved for long term basis, growing awareness about renal fibrosis treatment, and constant technological innovation leading to development of new, more advanced, safer and effective therapies. Government initiatives for development of novel drugs is expected to fuel growth of the global kidney fibrosis treatment market. Changing lifestyle and food habits are causing a rise in kidney fibrosis patient pools, which is expected to boost demand for kidney fibrosis treatment. Mounting health awareness and health concerns among the growing populations are the factors driving growth of the target market.
Point-of-care drug delivery systems, introduction of personalized medicines, mono-therapeutic approaches or combination therapies are the opportunities expected for growth of kidney fibrosis treatment market. However, high cost involved and failure of treatments are some factors restraining growth of the global kidney fibrosis treatment market to a certain extent. This is a trend expected to continue over the forecast period.
The global kidney fibrosis treatment market report has been segmented on the basis of therapeutics, end user, and region.
North America dominates the global kidney fibrosis treatment market in terms of revenue share, followed by the market in Europe due to large and increasing aging patient pool and improving health facilities globally. Asia Pacific is projected to be the fastest growing market over the forecast period due to increasing medical expenditure, rising medical treatment, and rise in disposable income.
To Get Sample Copy of Report visit @ https://marketresearch.biz/report/kidney-fibrosis-treatment-market/request-sample/
Key players in the global kidney fibrosis treatment market report include F. Hoffmann-La Roche Ltd., Pfizer, Inc., La Jolla Pharmaceutical Company, Merck & Co., InterMune, Inc., Galectin Therapeutics, Inc., ProMetic Life-Sciences Inc., Genzyme Corporation, and BioLine Rx Ltd.
Main attractions of the market report:
— Analysis of upcoming and past market information will help in structuring and outlining of current business strategies.
— A detailed information of players, their business strategies will advantageous in understanding the consumer demands and market scope.
— advancement opportunities and forecast buyer requests will immediate the collection of revenue.
— The most latest subtle elements industry revise, product launching events, production network study, growth and risk factors included which will help in speculation feasibility analysis.
Click here to view original web page at Global Kidney Fibrosis Treatment Market Potential, Production, Consumption Analysis Forecast 2027